hotspot -WSS

hotspot

author：comprehensive 2025-09-28 02:30:29 - browse：9544

What do CEOs owe the world? Did Humira break the system? And can you CRISPR a fetus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Then, we dive into the fascinating world of fetal genome surgery, as STAT’s Megan Molteni joins us to explain the work of a scientist named Tippi MacKenzie.

For more on what we cover, here’s the news on Gonzalez; here’s the story on MacKenzie; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Organ aging and disease risk measured by new blood test

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

UnitedHealth’s Optum accused of antitrust violations in California

Takeda, Janssen join wearable maker to measure scratching

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

BIO selects John Crowley as new CEO

focus

hotspot

focus

Moonlake's readout produced a cash windfall. Risks remain

UnitedHealth’s Optum accused of antitrust violations in California

Psychedelics group wrestles with new pharma identity

A disappointing year of Humira biosimilars

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

In age of alternative facts, a scholarly course on calling out crap

Organ aging and disease risk measured by new blood test

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A disappointing year of Humira biosimilars

focus

Biden report: The neurospychology of memory and aging

Mayo Clinic plans $5B tech

Industry veterans launch new biotech VC with $310M

Gilead might be held responsible for not developing a drug

ReNAgade cuts staff seven months after raising $300 million

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

explore

hotspot

leisure time

knowledge